Recent News
Read ArticleThe last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
https://t.co/HfzSPVbcBl https://t.co/n6FKX34j8p
Dr. John Cush @RheumNow ( View Tweet)
SLE Pipeline of New Therapies
Dr. Andrea Fava, EULAR 2026 in London.
https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF
Dr. John Cush @RheumNow ( View Tweet)
Treat to Target Works in Elderly Onset RA
Dr. Jiha Lee reports on abstract POS1326 at EULAR 2026 in London
https://t.co/X4vhR9KofC https://t.co/TSquFmZJCP
Dr. John Cush @RheumNow ( View Tweet)
Digital Platforms and AI
Work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.
https://t.co/LxXeFdAbU7 https://t.co/ocqSBhYHEf
Dr. John Cush @RheumNow ( View Tweet)
Digital Patient Education in RA
Dr. Bella Mehta reviews abstract OP005-HPR presented in London at EULAR 2026
https://t.co/Wj8omKJTNx. https://t.co/h13p54BAHs
Dr. John Cush @RheumNow ( View Tweet)
Understanding Comorbidities in RMD
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
Dr. John Cush @RheumNow ( View Tweet)
All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB.
Dr. John Cush @RheumNow ( View Tweet)
Day 1 Report from EULAR 2026
The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day. https://t.co/qCnoiGedat
Dr. John Cush @RheumNow ( View Tweet)
The pain that inflammation does not explain in SpA and PsA
At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1
Dr. John Cush @RheumNow ( View Tweet)
#TYK2i #deucravacitinib
#RCT in #SLE
LTE of #PAISLEY #RCT PERSISTENT #LLDAS &#DORIS #remission over 3 more yrs post 1 yr RCT BUT ++dropouts
#POS0695 #EULAR2026 @RheumNow https://t.co/vtrMYrFmJ9
Janet Pope @Janetbirdope ( View Tweet)
Who does better in active #RA
b/tsDMARD naive?
Pt choice TNFi or JAKi
OR
Pt randomized to
TNFI or JAKi?
Strangely or not
PT choice did better
✅with satisfaction ~maybe expected
✅better retention on chosen #Rx
🤔unexpected
another arm in #RCTS?”
#EULAR2026 @RheumNow
OP0204 https://t.co/7qx5Rqq6a7
Links:
Janet Pope @Janetbirdope ( View Tweet)
Can you step down #belimumab
In well controlled #SLE without flaring?
N=22 on #BEL eligible of 152
Able to taper if
REM >6/12
No #steroids
Normal C3,C4
Neg #antiDNA
Remission maintained in pts who reduced dose
6/22 didn’t flare OFF Rx
✅nice
#POS1052 #EULAR2026
@RheumNow https://t.co/IEyfRtTGfT
Links:
Janet Pope @Janetbirdope ( View Tweet)
A bridge to uncertainty?
large #RCT of #baricitinib V #TNFi
In
Active #RA w #DVT/#VTE risk factor(s)
Sl more VTE, #infection #SIE on #Bar
NO increase #MACE
Sl ⬆️#malignancy
#VTE rate exceeded upper limit of a priori #CI
So is this good news or not?
#LB0009 @RheumNow #EULAR2026 https://t.co/CIfU7TL2TE
Janet Pope @Janetbirdope ( View Tweet)
#EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃
https://t.co/fONe6g4ne1 https://t.co/kOqzF8t64w
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet)
#EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with Obinutuzumab in #lupus nephritis @RheumNow
https://t.co/V9CNdPsLcV https://t.co/WLVFyaSSUE
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
Dr. John Cush @RheumNow ( View Tweet)
This study evaluated the risk of flares after sustained drug-free rem in SLE.
% of pts w/ reported flares w/n yrs in rem:
48.6% at 2yrs
42.3% at 3yrs
35.2% at 5 yrs
Mucocut, msk, renal & immuno - ⬆️affected domain
Reassess pts regularly.
POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh
sheila @RHEUMarampa ( View Tweet)
@RheumNow article further exploring the roe of lung ultrasound for RA-ILD screening as shown through 3 #EULAR2026 abstracts
https://t.co/smN8hg51nj
Jiha Lee @JihaRheum ( View Tweet)
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow https://t.co/IhGQSxssyd
Links:
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
Video
From the Blog
Podcasts
EULAR 2026 Daily Podcast Day 4b-
EULAR 2026 Daily Podcast Day 4a
Day 4 Recap EULAR 2026-
EULAR 2026 Daily Podcast Day 3a
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
